Sarepta Therapeutics annual gross profit
2016
2022
2023
2024
2025
Sarepta Therapeutics Gross Profit Growth & History (SRPT)
Sarepta Therapeutics's gross profit was $1.84B for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.84B | $255.9M | +16.17% |
| 2024 | 2024-12-31 | $1.58B | $489.9M | +44.82% |
| 2023 | 2023-12-31 | $1.09B | $300.0M | +37.83% |
| 2022 | 2022-12-31 | $793.0M | — | — |
| 2016 | 2016-12-31 | $5.3M | — | — |
Sarepta Therapeutics quarterly gross profit
Q4.16
Q1.17
Q2.17
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $251.9M | −$108.7M | −30.15% |
| Q1 2026 | 2026-03-31 | $622.0M | $148.1M | +31.24% |
| Q4 2025 | 2025-12-31 | −$29.1M | −$535.0M | — |
| Q3 2025 | 2025-09-30 | $219.3M | −$118.8M | −35.14% |
| Q2 2025 | 2025-06-30 | $360.6M | $44.6M | +14.10% |
| Q1 2025 | 2025-03-31 | $474.0M | $165.0M | +53.42% |
| Q4 2024 | 2024-12-31 | $505.9M | — | — |
| Q3 2024 | 2024-09-30 | $338.1M | — | — |
| Q2 2024 | 2024-06-30 | $316.0M | — | — |
| Q1 2024 | 2024-03-31 | $308.9M | — | — |
| Q2 2017 | 2017-06-30 | $34.5M | — | — |
| Q1 2017 | 2017-03-31 | $16.1M | — | — |
| Q4 2016 | 2016-12-31 | $5.3M | — | — |
Sarepta Therapeutics gross profit trends
Between the periods ended 2016-12-31 and 2025-12-31, Sarepta Therapeutics's gross profit increased from $5.3M to $1.84B, a change of $1.83B. The latest reported quarter, Q2 2026, shows $251.9M.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...